Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

ConclusionsThe development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research